Sialoadhesin (Sn) expression has been demonstrated on murine and rat macrophages in lymphatic organs and is recognized by the monoclonal antibody (mAb) ED3 in the rat. Sialoadhesin (Siglec-1), the ED3 antigen in the rat, is a subtype of sialic acid -binding Ig-like lectins (Siglecs) that bind specifically to sialic acid-containing structures such as selectins and was originally identified as the sheep erythrocyte receptor (SER) responsible for sialic acid-dependent binding of native sheep erythrocytes (SE) to resident murine bone marrow macrophages in rosetting assays. The aim of the present study was to investigate the expression and potential function of sialoadhesin in the stratified squamous epithelium of the rat tongue, esophagus and skin. The expression of sialoadhesin was demonstrated by immunohistochemical analysis with the mAb ED3. This study demonstrated not only the presence of sialoadhesin on the basal epithelial cells of the stratified epithelium in normal rat tongue, esophagus and skin but also its upregulated expression on these cells in CY-treated rats. The results of the present study shed some light on the potential function of sialoadhesin in the basal epithelial cells of the stratified epithelium. Further studies may provide more insight into the role of sialoadhesin in the epithelial stem cells.
Animals ; Bone Marrow ; Cyclophosphamide* ; Epithelial Cells* ; Epithelium* ; Erythrocytes ; Esophagus ; Lectins ; Macrophages ; N-Acetylneuraminic Acid ; Rats* ; Selectins ; Sheep ; Sialic Acid Binding Ig-like Lectin 1 ; Skin ; Stem Cells ; Tongue ; Up-Regulation*

BACKGROUND: This study investigated the effects of Korean red ginseng (KRG) supplementation on metabolic parameters, inflammatory markers, and arterial stiffness in subjects with metabolic syndrome. METHODS: We performed a randomized, double-blind, placebo-controlled, single-center study in 60 subjects who were not taking drugs that could affect metabolic and vascular functions. Subjects were randomized into either a KRG (4.5 g/d) group or a placebo group for a 12-week study. We collected anthropometric measurements, blood for laboratory testing, and brachial-ankle pulse wave velocity (baPWV) at the initial (week 0) and final (week 12) visits. RESULTS: A total of 48 subjects successfully completed the study protocol. Oral administration of KRG did not significantly affect blood pressure, oxidative or inflammatory markers, or baPWV. CONCLUSION: We found no evidence that KRG had an effect on blood pressure, lipid profile, oxidized low density lipoprotein, fasting blood glucose, or arterial stiffness in subjects with metabolic syndrome. These findings warrant subsequent longer-term prospective clinical investigations with a larger population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00976274
Administration, Oral ; Blood Glucose ; Blood Pressure ; Fasting ; Lipoproteins ; Lipoproteins, LDL ; Panax ; Pulse Wave Analysis ; Vascular Stiffness